Rocket Lab Delivered 835% Returns in Five Years, Is It Still A Buy?

Rocket Lab’s defense-led transformation is supported by a $2.20 billion backlog, 70+ contracted missions, and an $816 million Space Development Agency award for 18 Tracking Layer satellites. Electron delivered 21 successful missions in 2025 at a 100% success rate, while Q1 2026 revenue grew 63.5%; however, Neutron slipped to Q4 2026 and FY2025 free cash flow was still negative $321.8 million. The stock remains highly volatile, but the article argues the business quality and contract pipeline have materially improved since its August 2021 SPAC debut.

Analysis

RKLB is increasingly behaving like a defense-enabled capital intensity story rather than a pure launch beta, which matters because the market is starting to price backlog as if it were near-term revenue certainty. The second-order effect is that every successful program award lowers perceived customer concentration risk and expands the addressable investor base from space-thematic traders to defense multiples, but that re-rating only holds if execution cadence stays intact through the Neutron transition. In other words, the stock is less about launch counts now and more about whether management can convert credibility into a durable, multi-year margin structure before the valuation outruns the operating base.

The key risk is timing asymmetry: defense awards and hype can re-rate the stock in days, while Neutron delays or integration friction from acquisitions can impair the thesis over quarters. Because the equity is already trading like an options contract on future platform success, any slippage in first-flight timing or evidence that backlog is slower-to-bill than expected could compress the multiple abruptly. Conversely, a clean Neutron milestone should matter disproportionately because it unlocks a narrative shift from "services plus components" to a vertically integrated launch-and-defense platform.

The consensus appears to be underestimating how reflexive this tape can become if sector sentiment remains favorable: a space-sector IPO or comparable comp expansion can lift RKLB even without fundamental inflection. But the move is also potentially overextended because high-growth defense-adjacent names often price perfection well before free cash flow turns, and the market tends to punish any capex or schedule surprise faster than it rewards contract wins. The real question is not whether RKLB is improving; it is whether the current market cap is already discounting the best-case Neutron and defense monetization path.

Key Decisions for Investors

• Go long RKLB only as a tactical position, sized small, with a 3-6 month horizon into Neutron milestones; prefer entry on post-rally pullbacks because upside is tied to catalyst realization rather than steady compounding.
• Use RKLB call spreads instead of outright equity for event exposure over the next 2-4 quarters; the stock’s beta and valuation sensitivity make defined-risk convexity superior to common shares if Neutron timing slips.
• Pair trade: long RKLB / short a lower-growth aerospace prime or launch proxy if you want pure defense-space upside; this isolates the re-rating from program wins while limiting broad sector beta.
• If already long, hedge with trailing downside protection after large gap-ups; a 20-30% drawdown can occur quickly on schedule risk, so protect gains rather than waiting for fundamental deterioration.
• Watch for confirmation from backlog conversion and margin trajectory over the next 1-2 earnings prints; if revenue growth remains >40% but operating losses do not narrow, take profits because the market may stop paying for narrative alone.